Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol for QoR-15 in Spine Surgery
NCT04994704Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of remimazolam in Ossification of the Posterior Longitudinal Ligament (OPLL) and cervical spondylotic myelopathy (CSM) (2 arms), sponsored by Gangnam Severance Hospital. Primary endpoint: Quality of Recovery-15 Score at 1 day. Started Dec 2021; status: completed.
02
Drugs
remimazolam
03
Conditions
Ossification of the Posterior Longitudinal Ligament (OPLL)cervical spondylotic myelopathy (CSM)
Beyond the preview
Go deeper on NCT04994704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994704.